ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases- Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier- ABL Bio to receive up to £77 million in upfront and near-term payments SEONGNAM, South Korea, April 6, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerativ ...